Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 13

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 13
---

are located at 101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www.clearmindmedicine.com/.
The information contained on our website and available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only.

<div align='center'>S-4</div>

THE OFFERING

| Common Shares offered by us                         |     | 10,925,000 Common Shares.                     |
| Common Shares outstanding prior to the offering     |     | 22,181,024 Common Shares.                     |
| Common Shares to be outstanding after this offering |     | 33,106,024 Common Shares.                     |
| Offering price                                      |     | The offering price is $0.20 per Common Share. |

| Use of proceeds                 |     | We intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures. See “Use of Proceeds” on page S-14 of this prospectus supplement. |
| Risk factors                    |     | Investing in the Common Shares involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to invest in the Common Shares.                                    |
| Nasdaq Capital Market           |     | “CMND”                                                                                                                                                                                                                                                                                                                                                                                              |
| Frankfurt Stock Exchange symbol |     | “CSE”                                                                                                                                                                                                                                                                                                                                                                                               |

Unless otherwise stated, all information in this prospectus is based on 22,181,024 Common Shares outstanding as of November 18, 2025, and does not include the following as of that date:

| ● | 11,927,606 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from $0.20 to $243.75, all of which were vested as of such date;                                                                        |
| ● | 5,521 common shares issuable upon the exercise of options to directors, employees and consultants under our incentive option plan outstanding as